We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against ...

NEW YORK, NY / ACCESS Newswire / April 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Collegium Pharmaceutical reported revenues of $181.9 million, up 21.5% year on year. This print exceeded analysts’ ...

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note released on Tuesday morning. Separately ...

Supernus' neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients ...

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system ...

Supernus Pharmaceuticals stock opened at $33.05 on Monday. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a fifty day simple moving average of ...